Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site.Himmel, D.M., Maegley, K.A., Pauly, T.A., Bauman, J.D., Das, K., Dharia, C., Clark, A.D., Ryan, K., Hickey, M.J., Love, R.A., Hughes, S.H., Bergqvist, S., Arnold, E.
(2009) Structure 17: 1625-1635
- PubMed: 20004166
- DOI: 10.1016/j.str.2009.09.016
- Primary Citation of Related Structures:
- PubMed Abstract:
- Crystal Engineering of HIV-1 Reverse Transcriptase for Structure-based Drug Design
Bauman, J.D., Das, K., Ho, W.C., Baweja, M., Himmel, D.M., Clark Jr., A.D., Oren, D.A., Boyer, P.L., Hughes, S.H., Shatkin, A.J., Arnold, E.
(2008) Nucleic Acids Res 36: 5083
Novel inhibitors are needed to counteract the rapid emergence of drug-resistant HIV variants. HIV-1 reverse transcriptase (RT) has both DNA polymerase and RNase H (RNH) enzymatic activities, but approved drugs that inhibit RT target the polymerase. I ...
Novel inhibitors are needed to counteract the rapid emergence of drug-resistant HIV variants. HIV-1 reverse transcriptase (RT) has both DNA polymerase and RNase H (RNH) enzymatic activities, but approved drugs that inhibit RT target the polymerase. Inhibitors that act against new targets, such as RNH, should be effective against all of the current drug-resistant variants. Here, we present 2.80 A and 2.04 A resolution crystal structures of an RNH inhibitor, beta-thujaplicinol, bound at the RNH active site of both HIV-1 RT and an isolated RNH domain. beta-thujaplicinol chelates two divalent metal ions at the RNH active site. We provide biochemical evidence that beta-thujaplicinol is a slow-binding RNH inhibitor with noncompetitive kinetics and suggest that it forms a tropylium ion that interacts favorably with RT and the RNA:DNA substrate.
Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08854-8021, USA. Electronic address: firstname.lastname@example.org.